Gabapentin Capsule
Product Images NDC 72162-2140

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 72162-2140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

A mathematical formula for calculating creatinine clearance (CLCr), shown as [(140 – age in years) × weight in kg] divided by [72 × serum creatinine in mg/dL], with a multiplier of 0.85 applied for female patients.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of Gabapentin, showing a cyclohexane ring attached to an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

Line graph showing mean pain score over 8 weeks comparing placebo versus Gabapentin 3600 mg/day. The x-axis represents time in weeks, including a 4-week dose titration period and a 4-week fixed dose period, while the y-axis shows mean pain score. Gabapentin line decreases over time, placebo remains relatively stable.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph depicting mean pain scores over a 7-week period for three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks from baseline through a 3-week dose titration and a 4-week fixed dose period. The y-axis shows mean pain scores, ranging from 0 to 10. Gabapentin groups show a decline in pain scores compared to placebo.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing results from two studies. Study 1 compares placebo (12%) with GBP 3600 (29%). Study 2 compares placebo (14%) with GBP 1800 (32%) and GBP 2400 (34%). Statistical significance is indicated with p-values below 0.01 and 0.001 for GBP groups versus placebo.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing the percentage difference across three studies labeled a, b, and c against daily doses of 600 mg, 900 mg, 1200 mg, and 1800 mg. The y-axis shows difference (%) ranging approximately from 2 to 22, and the x-axis shows daily dose (mg). Black, gray, and white squares represent Study a, Study b, and Study c respectively, showing variation in differences at each dose level.*

FDA Label Image

Label (Lbl721622140)

Gabapentin Capsules USP 400 mg oral capsules label showing a quantity of 100 capsules. The label indicates the product is relabeled by Bryant Ranch Prepack and manufactured by ACI Healthcare Limited. The label includes storage instructions, dispensing requirements, and a barcode alongside the NDC 72162-2140-1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.